Phases, active trials: Phase 1: 60, Phase 2: 123, Phase 3: 193, Other: 177
AstraZeneca operates one of the broadest oncology pipelines in the industry, with particular depth in lung cancer (Tagrisso/osimertinib and successors), ovarian and breast cancer (Lynparza/olaparib), and immuno-oncology (Imfinzi/durvalumab). The AstraZeneca/Daiichi-Sankyo collaboration on antibody-drug conjugates — including Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan — has reshaped the ADC landscape across HER2-expressing tumors. Outside oncology, AstraZeneca's CVRM franchise (Farxiga/dapagliflozin, Brilinta/ticagrelor) continues expanding indications into heart failure and chronic kidney disease.
- Oncology
- Lung cancer (EGFR/ALK/HER2)
- Ovarian cancer
- Breast cancer ADCs
- Cardiovascular / Metabolic
- Rare disease
- Tagrisso (osimertinib) — EGFR-mutant NSCLC
- Lynparza (olaparib) — BRCA-mutated cancers
- Imfinzi (durvalumab) — PD-L1 checkpoint
- Enhertu (trastuzumab deruxtecan) — HER2 ADC
- Dato-DXd (datopotamab deruxtecan) — TROP2 ADC
- Calquence (acalabrutinib) — B-cell malignancies
Monitor the AstraZeneca pipeline daily
Get a daily digest when AstraZeneca registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Breast Cancer | 23 |
| Asthma | 17 |
| Non-small Cell Lung Cancer | 16 |
| Systemic Lupus Erythematosus | 15 |
| Hepatocellular Carcinoma | 14 |
| Non-Small Cell Lung Cancer | 14 |
| Gastric Cancer | 13 |
| Ovarian Cancer | 12 |
AstraZeneca registers new combination trials for its ADC portfolio monthly. Monitoring their pipeline helps identify new competitive entries into HER2, TROP2, and EGFR-targeted spaces before they appear in analyst reports.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to AstraZeneca's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: AstraZeneca may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your AstraZeneca pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia NCT06137118 | Recruiting | Completion pushed: 2027-06-29 → 2028-09-15 | 2026-08-20 |
| A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in… NCT06271837 | Active, Not Recruiting | Primary completion pushed: 2025-11-28 → 2027-02-10 | 2026-09-04 |
| Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab NCT07363642 | Recruiting | Primary completion pushed: 2027-08-07 → 2028-02-07 | 2026-09-04 |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or… NCT06921785 | Recruiting | Primary completion pushed: 2029-03-16 → 2030-03-15 | 2026-09-04 |
| Study of Patient With Frequent Exacerbations in Moscow NCT07307781 | Recruiting | Enrollment reduced: 500 → 300 participants | 2026-09-04 |
Each trial page shows every change DataLookout has recorded for that trial.